Besides the issue of some sort of chemical transformation in the body, another possibility is the method of delivery was not optimal/correct (the molecule never got to the target tissue, presumably a tumor) and another is that the formulation of the drug was not stable (the molecule was delivered as another, altered molecule which did not have the desired activity. Sometimes these things happen when one company produces a drug formulation and another company, that doesn't have knowledge of the drug stability and how to deliver it, conducts a pre-clinical or clinical study.
For the study, the drug should have been administered as a IV bolus or perhaps in a sustained fashion via a mini-pump, thus avoiding the GI tract and the first-pass metabolism. The explanation rings a little strange to me, unless the drug was administered orally (this would be weird for an animal model) or subQ.
I am curious which three (?) drugs were tested? Was one of them Andro Car? This was the one that originally got me excited about this company. I think that the administration was oral. Also, I am wondering what we are trading at these days.
In any case, it sounds like they are serious about researching the anti-cancer activity of their extracts, and that is good news for everyone. I am still very interested in this area, although I remain on the sidelines for now.
Good luck everyone,
Rick |
